Ireland
--:--IST
Latest
Clinical Trials in Canada / NCT06315725
Recruiting Observational

Effect of Artificial Sweetener (AFS) on Glucose Metabolism in Patients with Type 1 Diabetes (T1D)

NCT06315725 · tracked via the Priya Life Science Canada tracker
Phase
Observational
Started
2024-11-12
Last updated
2024-11-22

Condition(s) studied

Type 1 Diabetes (T1D)Healthy Subjects

Investigational drug(s) / intervention(s)

Sweet taste perception with/without sweet taste blockade

Sweet taste perception with/without sweet taste blockade: In our study, we will use our four different novel flavored beverages, with and without a sweet taste blockade.

Study summary

The goal of this randomized crossover study is to test the prediction that consuming carbohydrates will affect insulin release differently depending on whether Non-Nutritive Sweeteners (NNSs) are consumed simultaneously. We aim to determine whether the predicted effects are associated with oral or post-oral sweet taste receptor signaling,. Our study will focus on patients diagnosed with type 1 diabetes (T1D) who are using an artificial pancreas (AP) system, as it allows us to monitor glucose and insulin levels over time.

Participants will drink four different flavored beverages, some with sweet taste blockade and some without, in a counter-balanced order. They will then rate the sweetness of each beverage, and we will collect data from their AP system to monitor insulin and glucose level.

To achieve this, we will conduct a pilot study to assess the effectiveness and best timing of sweet taste blockade in healthy individuals. Insights gained from the pilot study will inform the main study.

Sucralose will be used as the NNS, maltodextrin as the carbohydrate, and Gymnema Sylvestre (GS) as the sweet taste receptor blocker.

Eligibility

Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Participants with a diagnosis of T1D * HbA1C ≤ 8 % * Insulin pump therapy * Adults of any gender or biological sex aged 18-45 years old, * Body Mass Index (BMI) between 18.5-29.9 kg/m, * Non-smokers, * English or French speaker. ●. Who can consume chicken and fish Exclusion Criteria: * A major medical diagnosis that could potentially influence metabolic dysfunction * A major medical diagnosis other than T1D, * Alcohol or substance use disorder, * Eating disorder or history of malabsorptive syndrome, * Inflammatory bowel disease, * Self-reported impairment in taste or smell, * A known taste or smell dysfunction (e.g., anosmia), * Active pregnancy and/or lactation, * Food allergies or intolerances, * Dislike of the test beverages, * History of bariatric surgery at any point in the past ●. Regular consumer of Gymnema sylvestre

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Center for Innovative Medicine, The Research Institute of the McGill University Health Centre Montreal Quebec Recruiting

More McGill University Health Centre/Research Institute of the McGill University Health Centre trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06315725 on ClinicalTrials.gov ↗ ← All trials in Canada